SCHEMBL23906102

SCHEMBL23906102

COc1cc(C(=O)O)ccc1-c1nc(C(C)C)c(-c2ccc(F)cc2)c2cc3cn[nH]c3cc12

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ROCK2 O75116 6/20 0.40
ROCK1 Q13464 4/20 0.40
MAOB P27338 4/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
CYP1A2 P05177 1/20 0.36
METAP2 P50579 1/20 0.36
TLR8 Q9NR97 1/20 0.36
FYN P06241 1/20 0.36
SRC P12931 1/20 0.36
TEC P42680 1/20 0.36
BTK Q06187 1/20 0.36
ITK Q08881 1/20 0.36
CTNNB1 P35222 1/20 0.36
WNT3A P56704 1/20 0.36
MKNK1 Q9BUB5 1/20 0.35
HSP90AA1 P07900 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23906060 0.90 CTNNB1 (0.38) MAOBNPC1RAB9ACTNNB1WNT3A
SCHEMBL25474980 0.87 MAPK1 (0.44) ROCK1MAOBNPC1RAB9ABTK
SCHEMBL23905477 0.87 TTR (0.36) ROCK2ROCK1MAOBNPC1RAB9A
SCHEMBL23906350 0.86 ROCK1 (0.37) ROCK2ROCK1NPC1RAB9ATLR8
SCHEMBL23906101 0.85 ROCK1 (0.40) ROCK2ROCK1MAOBNPC1RAB9A
SCHEMBL23884844 0.84 ROCK2 (0.39) ROCK2ROCK1MAOBNPC1RAB9A
SCHEMBL30251761 0.84 ROCK2 (0.39) ROCK2ROCK1MAOBNPC1RAB9A
SCHEMBL23906094 0.81 CTNNB1 (0.37) ROCK2MAOBNPC1RAB9ACTNNB1
SCHEMBL23905630 0.81 MAOB (0.42) ROCK2ROCK1MAOBNPC1RAB9A
SCHEMBL23906351 0.81 CTNNB1 (0.36) ROCK2ROCK1NPC1RAB9ACTNNB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159521-A1 1H-PYRAZOLO[4,3-G]ISOQUINOLINE AND 1H-PYRAZOLO[4,3-G]QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) VERTEX PHARMACEUTICALS INCORPORATED 2023-05-25 US disclosed
US-20230159521-A1 1H-PYRAZOLO[4,3-G]ISOQUINOLINE AND 1H-PYRAZOLO[4,3-G]QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) VERTEX PHARMACEUTICALS INCORPORATED 2023-05-25 US disclosed
WO-2021203025-A1 1 H-PYRAZOLO[4,3-G]ISOQUINOLINE AND 1 H-PYRAZOLO[4,3-G]QUINOLINE DERIVATIVES AS ALPHA-1 -ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1 -ANTITRYPSIN DEFICIENCY (AATD) VERTEX PHARMACEUTICALS INCORPORATED (US) 2021-10-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159521-A1 1H-PYRAZOLO[4,3-G]ISOQUINOLINE AND 1H-PYRAZOLO[4,3-G]QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) SERPINA2, SERPINE1, SERPINA3 ROCK2 3138/4885ROCK1 1434/4885MAOB 2709/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.